Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules

• Main Authors: Alessia Biolchi (Author), Sara Tomei (Author), Laura Santini (Author), Jo Anne Welsch (Author), Daniela Toneatto (Author), Nikolaos Gaitatzis (Author), Xilian Bai (Author), Ray Borrow (Author), Marzia Monica Giuliani (Author), Elena Mori (Author), Mariagrazia Pizza (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The 4-component vaccine 4CMenB, developed against invasive disease caused by meningococcal serogroup B, is approved for use in infants in several countries worldwide. 4CMenB is mostly used as 3 + 1 schedule, except for the UK, where a 2 + 1 schedule is used, and where the vaccine showed an effective...